Skip to main content
OpenTrials
Completed

NCT Number: NCT00288509

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

The aim of this study is to assess longer term safety and effectiveness of Dysport®.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cervical Dystonia Dyskinesias Dystonia Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Torticollis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Clinic "Cecil Plus", Moscow, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects enrolled in the Y-47-52120-051 study, who have completed all study visits up to Week 12, or up to Week 4 in the event of an early withdrawal
  • Returned to pre-treatment status as judged by the Investigator

Exclusion criteria

  • Pure anterocollis or pure retrocollis
  • Known antibodies to botulinum toxin type A
  • Requirement for botulinum toxin injections to site(s) other than the neck and unable to avoid such treatment for the duration of the study
  • Known significant underlying swallowing or respiratory abnormality which might be exacerbated by botulinum toxin treatment

Treatment and study plan

Botulinum toxin type A

Biological

In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety & efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.

Other names: AbobotulinumtoxinA (Dysport®)

Primary outcomes

  1. Change in Toronto Western Spasmodic Torticollis Rating Scale Total Score From Baseline

    Time frame: Week 4 follow-up visit

    TWSTRS is comprised of three different components which are severity, disability & pain. There is an ordinal scale for each component and the score range for each is the following: for severity from 0 (absence of severity) to 35 (max severity), for disability from 0 (no disability) to 30 (max disability) and for pain from 0 (no pain) to 20 (max pain). TWSTRS total score is the sum of the 3 component scores, with a range from 0 to a maximum of 85. For each treatment cycle, the change in TWSTRS total score is the score at week 4 minus the score at baseline.

Secondary outcomes

  1. Toronto Western Spasmodic Torticollis Rating Scale Severity Subscale as a Change From Baseline

    Time frame: Week 4 follow-up visit

    TWSTRS is comprised of three different components which are severity, disability & pain. There is an ordinal scale for each component and the score range for severity is from 0 (absence of severity) to 35 (max severity). For each treatment cycle, the change in TWSTRS severity subscale is the score at week 4 minus the score at baseline.

  2. Toronto Western Spasmodic Torticollis Rating Scale Disability Subscale Score as a Change From Baseline

    Time frame: Week 4 follow-up visit

    TWSTRS is comprised of three different components which are severity, disability & pain. There is an ordinal scale for each component and the score range for disability is from 0 (no disability) to 30 (max disability). For each treatment cycle, the change in TWSTRS disability subscale is the score at week 4 minus the score at baseline.

  3. Toronto Western Spasmodic Torticollis Rating Scale Pain Subscale Score as a Change From Baseline

    Time frame: Week 4 follow-up visit

    TWSTRS is comprised of three different components which are severity, disability & pain. There is an ordinal scale for each component and the score range for pain is from 0 (no pain) to 20 (max pain). For each treatment cycle, the change in TWSTRS pain subscale is the score at week 4 minus the score at baseline.

Sponsors and collaborators

Lead sponsor

Ipsen

Industry

Registry information

Official study title

A Phase III, Prospective, Multicenter, Open-label Extension Study to Assess the Longer Term Safety and Efficacy of Repeated Treatment of Dysport® Intramuscular Injection in the Treatment of Cervical Dystonia

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Feb 8, 2006
Registry last updated
Sep 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.